Evidence map›Paper›PMID 39262575›Full record

ArticleDystonia (Lausanne, Switzerland)2024

Samira Saeirad, Mark S LeDoux

Abstract read
In one paragraph

Article in Dystonia (Lausanne, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Samira SaeiradDepartment of Psychology, University of Memphis, Memphis, TN, United States.
Mark S LeDouxDepartment of Psychology, University of Memphis, Memphis, TN, United States.

Funding

Pathobiology and Treatment of the UBTF E210K Neuroregression SyndromeR56NS123059 · NINDS · UNIVERSITY OF MEMPHIS · PI LEDOUX, MARK S · 2021 to 2021
$415k
Pathobiology of GNAL-Associated DystoniaR21NS123827 · NINDS · UNIVERSITY OF MEMPHIS · PI LEDOUX, MARK S · 2022 to 2023
$395k
NINDS NIH HHS R21 NS123827NINDS NIH HHS R56 NS123059
6 · The paper itself

Abstract

Introduction: In preceding work, a deleterious Methods: Sanger sequencing was used to screen subjects ( Results: No highly deleterious variant was identified in coding or contiguous splice site regions of Conclusion: Highly deleterious

Indexed as

blepharospasmdystoniagenetic variantREEP4Sanger sequencing

Identifiers

PMID39262575
PMCPMC11390104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.